Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

Fei Wang¹
Justine Surh¹
Manmeet Kaur²

¹University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, ²Joslin Diabetes Center Affiliate, Hospital of Central Connecticut, New Britain, CT, USA

Background: Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations.

Objective: The aim of this review is to assess the efficacy and safety data of IDeg in the treatment of type 1 and type 2 diabetes mellitus.

Methods: Relevant English language articles from 2010 to 2012 were identified through MEDLINE, PubMed, EMBASE, Scopus, BIOSIS, and Google Scholar. Online conference proceedings of the 71st ADA Scientific Sessions and the 47th EASD Annual Meeting were reviewed. Studies were compared in terms of their study designs, primary and secondary efficacy parameters, and tolerability data.

Results: There are a total of nine published trials investigating the clinical efficacy and safety of IDeg in over 3000 subjects with type 1 and 2 diabetes. Only three trials were published in full. All were open-label, randomized multicenter trials with durations of 16 to 52 weeks. IDeg and coformulations of IDeg with insulin aspart (IAsp) were compared to insulin glargine (IGlar), detemir, and biphasic IAsp 30 (BIAsp 30).

Conclusion: Based upon the available evidence, there appear to be no reported differences between IDeg and IGlar, detemir, or BIAsp 30 in the reduction of the primary efficacy end-points of HbA₁c and mean fasting plasma glucose (FPG) concentrations. Only flexible dosing of IDeg provided a significant reduction in FPG compared to IGlar. IDeg demonstrated a significant reduction in nocturnal hypoglycemia in type 1 diabetes. In type 2 diabetes, IDeg reduced the incidence of hypoglycemia by 18% and 58% compared to IGlar and BIAsp 30, respectively.

Keywords: basal insulin analog/analogue, degludec, degludec/aspart, IDeg, IDegAsp, NN1250, efficacy, safety, comparative study

Introduction

Insulin analogs are artificially modified insulin molecules that allow better mimicking of endogenous insulin availability and therefore better metabolic control of diabetes. The aim of basal insulin analogues is to provide glycemic control while reducing the risk of hypoglycemia compared with insulin neutral protamine Hagedorn (NPH) by providing a consistent absorption of insulin and a reduced insulin peak.¹ The two long-acting basal insulin analogs, glargine (IGlar) and detemir, represent clinically relevant advances over NPH insulin in optimizing basal insulin substitution, thus allowing tighter blood glucose control and lowering the risk of hypoglycemia and nocturnal hypoglycemia,²-⁴ while producing similar or lower fasting plasma glucose...
Insulin degludec
Insulin degludec (IDeg) is a neutral ultralong-acting new generation basal insulin analog that was developed by NovoNordisk (Bagsvaerd, Denmark) and which is currently in Phase III clinical development. IDeg offers a much longer duration of action than current basal insulin formulations, with a duration of action of more than 42 hours in adults. It has the potential to broaden the options for current diabetes treatment with a flexible thrice weekly \(^1^7\) dosing regimen that can be administered at any time of the day. \(^1^8\)-\(^2^0\) These characteristics will facilitate the integration of insulin therapy with daily activities and potentially improve adherence and acceptance of basal insulin treatment. Furthermore, in patients with type 1 diabetes, IDeg also improved psychological well-being and quality of life. \(^2^1\)

The IDeg molecule retains the human insulin amino acid sequence except for the deletion of threonine in the B30 position (ThrB30) and the addition of a 16-carbon fatty acid side chain attached to lysine in position B29 (LysB29) of the insulin B-chain via a glutamic acid linker. \(^2^2,2^3\) IDeg exists in a dihexameric state when in solution prior to administration. \(^2^4\) This structural modification is designed to allow IDeg to self-associate to form large multihexamer assemblies at the site of injection following subcutaneous administration, as the additives (phenol, m-cresol, and zinc) in the formulation disperse. \(^2^4\) Its ultralong effect is primarily a result of the slow release of IDeg monomers from soluble multihexamers, resulting in a depot from which IDeg is continuously and slowly absorbed into the circulation. \(^1^6,2^2,2^5\) This mechanism of action gives rise to an ultralong and flat action profile at steady state when administered to people with type 1 and type 2 diabetes.

The efficacy and safety of IDeg has been compared to IGLar \(^1^7^-^2^0,2^6^-^3^5\) and insulin detemir. \(^3^6\) In these studies, IDeg demonstrated comparable glycemic control, \(^1^7^-^2^0,2^6,2^8^-^3^4,3^6^-^3^8\) with lower rates of hypoglycemia \(^2^9,3^0,3^2,3^3,3^7,3^9\) and nocturnal hypoglycemia, \(^2^6,2^8,3^2,3^3,3^6\) suggesting a better tolerability profile as a result of improved pharmacokinetics. \(^2^4\)

IDeg is a clear solution of pH 7.4 with a pH-dependent solubility and an isoelectric point similar to that of human insulin. It is to be administered subcutaneously. As is the case for human insulin, each unit of IDeg solution contains 6 nmol of IDeg. \(^2^4\) IDeg is also being developed in a soluble coformulation with rapid acting insulin aspart (IAsp), which is referred to as IDegAsp or Degludec Plus. A size-exclusion chromatography of the coformulation product identified the formation of multihexamers composed distinctly of degludec under physiological conditions providing the basal insulin coverage, while rapid-acting IAsp was predominantly present as monomers, allowing fast absorption into the bloodstream. \(^4^0\) IDegAsp is a soluble formulation of basal insulin analog IDeg (70%) and IA (30%) and has been evaluated in a number of studies. \(^3^1,3^6^-^3^8,4^1\) An alternate formulation of 55% IDeg and 45% IA has also been studied. \(^3^8\) Two different formulations of IDeg insulin have also been compared: 100 U/mL (U-100) and 200 U/mL (U-200). The U-200 formulation of IDeg is twice as concentrated as traditional U-100 insulin formulations. Both of these formulations demonstrated bioequivalence and similar pharmacodynamic profiles at steady state without any marked differences in adverse or hypoglycemic events. \(^4^2\) The availability of a U-200 formulation in clinical practice has the potential to enable higher doses to be administered in a given injection volume.

Pharmacokinetics and pharmacodynamics
The PK and PD characteristics of IDeg have been studied in subjects with type 1 \(^1^6,2^2,2^3,3^5,4^2^-^4^5\) and type 2 diabetes. \(^2^5\)
These data are available only in abstract form as they were presented at conference proceedings. Multiple abstracts were published in both the 2011 American Diabetes Association (ADA) and European Association for the Studies of Diabetes (EASD) conference proceedings. A small unpublished study investigating the PK properties of IDeg in healthy subjects was completed at the end of 2011.

The PK and PD of IDeg in type 1 diabetes has been evaluated in eight small studies (n = 12–66) and has been compared to IGlar (Sanofi-Sa, Paris, France). The PK and PD of IDeg has been assessed in only one study (n = 49) of people with type 2 diabetes.

All of these studies used the euglycemic glucose clamp technique to measure PD profiles and within-subject variability estimated on log-transformed pharmacodynamic end-points derived from the glucose infusion rate profiles during the clamps. However, in the majority of studies, the method of glucose clamping (ie, manual versus using an automated “artificial pancreas”) was not revealed, so it is not possible to compare the data. Overall, information from these studies demonstrates that when IDeg is administered once daily under steady-state conditions it is significantly less variable within subjects and more stable in glucose-lowering effect than IGlar.

**Type 1 diabetes**

Evidence of a prolonged action profile of IDeg was first provided in a study by Jonassen et al in twelve subjects with type 1 diabetes. Following 6 days of subcutaneous injection with IDeg (5.0 nmol/kg, once daily), the mean steady state PK profile demonstrated a smooth and stable exposure over 24 hours. IDeg was found to have a t1/2 longer than 24 hours and was detectable in the circulation for at least 96 hours after the final injection, although it cannot be concluded from this that IDeg would still be biologically active at that time.

This information was confirmed in a 42-hour euglycemic clamp study of therapeutic doses of IDeg (0.4, 0.6, or 0.8 U/kg) administered subcutaneously once daily to 21 subjects. After 8 days, the steady state glucose-lowering effect of IDeg extended beyond 42 hours at all three doses. End of action (blood glucose (BG) >150 mg/dL) did not occur within the 42-hour clamp period for any subjects dosed with 0.6 or 0.8 U/kg IDeg and only for three of the 21 subjects on 0.4 U/kg IDeg. Moreover, mean blood glucose profiles measured over the 4-hour clamp remained almost horizontal for the 0.6 or 0.8 U/kg dose groups, showing that blood glucose was controlled throughout the 42-hour period.

The PK properties of IDeg also appeared to be preserved in children and adolescents with type 1 diabetes (n = 25) after a single (0.4 U/kg) dose of IDeg insulin. IDeg was detected 72 hours after administration for all subjects. Total exposure to IDeg (AUC) tended to be greater in children and adolescents than in adults, with no differences in maximum IDeg concentration (Cmax).

**Comparison with insulin glargine**

The PK properties of IDeg were compared to those of IGlar under steady state conditions in two studies in people with type 1 diabetes.

In a randomized, double-blind, two-period crossover trial, 66 people with type 1 diabetes (55 males and 11 females, mean age = 37 years, glycosylated hemoglobin [HbA1c] 8.1%, body mass index [BMI] 24.9 kg/m²) received one of three fixed doses (0.4, 0.6, or 0.8 U/kg) of IDeg and IGlar once daily for 8 days with 7–21 days of wash-out between treatments. A euglycemic glucose clamp was performed on treatment day 8, and PK samples were taken throughout each treatment period and for 120 hours after the last dose. IDeg showed stable PK concentrations under steady-state conditions, and demonstrated minimal fluctuations that increased proportionally with increasing dose. The serum exposure to IDeg was equally distributed between the first and the second 12-hour period post-dosing, whereas IGlar showed a higher exposure during the first 12 hours. Likewise, the cumulated AUC below and above the average glucose infusion rate was considerably lower for all doses of IDeg (0.25, 0.37, and 0.38 mg/kg/minute) than with IGlar (0.39, 0.54, and 0.73 mg/kg/minute). IDeg was detectable in the serum for at least 120 hours following the final dose, whereas IGlar fell below the lower limit of quantification 36–48 hours post-dosing for most subjects. Mean terminal half-life was twice as long for IDeg than IGlar (25.4 vs 12.5 hours). Both insulin preparations were well tolerated and no safety concerns were identified. This study concluded that IDeg has a half-life that is twice as long as that of IGlar, resulting in a more evenly distributed and stable PK profile, and a more stable and less variable glucose lowering effect than IGlar.

In a parallel group, randomized double-blind study, 54 people with type 1 diabetes (48 males and six females, mean age = 38 ± 10 years, mean HbA1c = 7.7% ± 0.9%, mean BMI = 24.6 ± 2.2 kg/m²) were treated with 0.4 U/kg IDeg or IGlar once daily for 12 days. On treatment days 6, 9, and 12, pharmacodynamic profiles were investigated over
24 hours with the glucose clamp technique (Biostator; Miles Laboratories, Elkhart, IN). IDeg produced significantly less pharmacodynamic variability than IGlar on all protocol pharmacodynamic variability parameters, including total metabolic effect \((P < 0.0001)\). The individual within-subject variability was consistently lower for IDeg compared with IGlar \((P < 0.001)\). IDeg’s metabolic effect was evenly distributed between the first and the second 12 hours, and this distribution was less variable than that seen with IGlar \((P < 0.001)\). Both insulin types were well tolerated, without serious adverse events and without severe hypoglycemic episodes. This study demonstrated that once daily administration of IDeg is significantly less variable and more stable in glucose lowering effect than IGlar. A post-hoc analysis confirmed that the lower within-subject variability of IDeg was consistent over time, whereas the variability of IGlar was higher and increased substantially after 8 hours post-dosing. \(^{44}\) In conclusion, the within-subject variability for IDeg is consistently and significantly \((4 \text{ times})\) lower than IGlar over 24 hours, which may be due to the slow release of IDeg monomers from soluble multihexamers that form after subcutaneous injection. IDeg’s lower within-subject variability is thought to contribute to the lower risk of hypoglycemia observed in clinical studies.

**Type 2 diabetes**

A double-blind, two-period crossover trial investigated the dose-response relationship of three doses of IDeg \((0.4, 0.6, \text{and } 0.8 \U{217B}k g)\) at steady state in 49 people with type 2 diabetes who were insulin-treated without concomitant oral antidiabetic agents (OADs). \(^{25}\) Participants \((\text{mean age } = 58.7 \text{ years}, \text{mean } HbA_1c = 7.6\%, \text{mean } \text{BMI} = 29.6 \text{ kg/m}^2, \text{mean duration of diabetes } = 14.1 \text{ years})\) were given IDeg once-daily for 6 days, with a washout period of 13 to 21 days between treatments. Following dosing on day 6, subjects underwent a euglycemic glucose clamp study. PK samples were taken up to 120 hours after the last injection of IDeg. For all dose levels, mean 24 hour glucose infusion rate (GIR) profiles were flat and stable. The total glucose-lowering effect of IDeg increased linearly with increasing dose. The terminal half-life estimated across the three dose levels after the last dose was 25.1 hours. IDeg was well tolerated and no safety concerns were identified. In summary, it is noteworthy that in all of these PK and PD glucose clamp studies, IDeg insulin at steady state demonstrated a flat action profile with a prolonged duration of action beyond 24 hours, a more stable blood glucose-lowering effect, and lower within-subject variability in subjects with both type 1 and type 2 diabetes. This data seems to support the once daily or three times a week administration of IDeg. \(^{17,34}\)

**Clinical trials**

All of the clinical trials summarized in Tables 1 and 2 were open-label phase II and III studies of IDeg sponsored by NovoNordisk. The primary efficacy endpoint was \(HbA_1c\) levels from baseline to end of study. Secondary efficacy endpoints were changes in FPG. Tolerability and safety variables in most trials included confirmed hypoglycemic and nocturnal hypoglycemic episodes, adverse events including injection-site reactions, and changes in body weight from baseline.

At the time of writing, there are three trials investigating the clinical efficacy and safety of IDeg in subjects with type 1 diabetes. One Phase II study was presented in full \(^{29}\) and in abstracts, \(^{30,47}\) and two Phase III studies were presented in abstract form at conference proceedings of the 2011 ADA \(^{20,37}\) and the EASD. \(^{26,38}\) Home et al \(^{48}\) reported an improved quality of life with IDeg compared to IGlar using data from the Phase II study. \(^{29}\) Both IGlar and insulin detemir are used as comparators, mostly in combination with IAsp. Table 1 shows a summary of these trials.

In type 2 diabetes, there are a total of six trials investigating the clinical efficacy and safety of IDeg. Two Phase II studies are available in full \(^{14,38}\) (parts of these studies are also presented in abstract form) \(^{17,31}\) and four studies (Phase II and III) are available only in abstract form \(^{18,20,32,33,41,49,51}\) and presented at multiple conference proceedings: ADA, \(^{18,33,41}\) EASD, \(^{19,20,32,49}\) and International Diabetes Federation. \(^{50,51}\) Table 2 shows a summary of these trials.

At the time of writing, there are several ongoing Phase III clinical trials in type 2 diabetes comparing the dual action of IDeg and liraglutide to IDeg alone, switching from IGlar to IDeg (BEGIN™), comparing two IDeg formulations, and comparing the efficacy and safety of two intensification strategies in subjects with type 2 diabetes inadequately controlled on basal insulin and metformin. \(^{52}\)

**Degludec in type 1 diabetes**

The clinical efficacy, safety, and tolerability of IDeg in subjects with type 1 diabetes were all assessed during short-term open-label trials with a duration of 16 weeks, \(^{29}\) 26 weeks, \(^{36,37}\) and 52 weeks. \(^{26,28}\) Only one study published in full demonstrated adequate power. \(^{29}\)
Table 1 Summary of clinical trials in patients with type 1 diabetes

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Duration (weeks)</th>
<th>Mean baseline values</th>
<th>Comparators</th>
<th>Basal insulin target goals</th>
<th>HbA1c, %</th>
<th>Change (±SD) from baseline to end of study</th>
<th>ETD (95% CI)</th>
<th>FPG, mg/dL (laboratory measured)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birkeland et al*</td>
<td>178</td>
<td>16</td>
<td>Age: 45.8; BMI: 26.9; HbA1c: 8.4; FPG: 178.2</td>
<td>IDeg1 vs IGlar</td>
<td>72–108</td>
<td>IDeg (A) – IGLAR: 0.57 (±0.76)</td>
<td>1D(IGlar): 0.10 (±0.1–0.3)</td>
<td>ETD (95% CI)</td>
<td>IDeg (A) vs IGlar: 3.10 (±3.10)</td>
</tr>
<tr>
<td>Phase II M, R, C, O</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IDeg (B) – IGlar: 0.62 (±0.68)</td>
<td>IGlar: 0.18 (±0.06–0.04)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hirsch et al*</td>
<td>548</td>
<td>26</td>
<td>Age: 41; HbA1c: 8.3; FPG: 189</td>
<td>IDegAsp (70/30) vs detemir</td>
<td>Not reported</td>
<td>IDegAsp – detemir: 0.68</td>
<td>IGlar: 0.05 (±0.2–0.08)</td>
<td></td>
<td>Detemir: 4.1 (±8.3–16.4)</td>
</tr>
<tr>
<td>Phase III O, R, treat-to-target</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Russell-Jones et al and Heller et al†,36,37</td>
<td>629</td>
<td>52</td>
<td>Age: 43; HbA1c: 7.7; FPG: 150</td>
<td>IDeg vs IGlar</td>
<td>&lt;90</td>
<td>IDeg (A) – IGlar: 0.4</td>
<td>IGlar: 0.01 (±0.04–0.11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III O, R, treat-to-target</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: *Trials using two formulations of insulin degludec (IDeg (A), 600 μmol/L, 1 unit/mL, 1 unit/9 nmol; IDeg (B), 900 μmol/L, 1 unit/9 nmol; IDeg (B) was discontinued following study (mean dose was decreased over the trial suggesting the starting dose for this higher strength was too high); †Abstract; ‡Full publication.

Abbreviations: M, multicenter; R, randomized; C, controlled; P, parallel-group; O, open-label; BMI, body-mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; IDeg, insulin degludec; IGlar, insulin glargine; IDegAsp is a soluble co-formulation of IDeg (70%) and insulin aspart (IAsp; 30%); ETD, estimated mean treatment difference.

In a 16-week, multicenter, open-label, three-arm parallel-group trial, 178 participants with type 1 diabetes (mean age = 24 years, mean HbA1c = 8.4%; mean FPG = 178 mg/dL (9.9 mmol/L), mean BMI = 26.9 kg/m²) were randomized to receive IDeg (A) 1500 units (95% CI: 1.27 mmol/L, 95% CI: 18.6–15.16), IDeg (B) 900 units (95% CI: 18.6–15.16), or IGlar 900 units (95% CI: 18.6–15.16) once daily in the evening. Insulin dose was adjusted to a FPG target of 72–108 mg/dL (4.0–6.0 mmol/L). Rates of nocturnal hypoglycemia were similar between insulin treatments. Rates of overall confirmed hypoglycemia were 25% lower for IDeg (A) (7.8% ± 0.8%) and IGlar (7.6% ± 0.8%) compared with IGlar (9.9% ± 0.8%). The estimated mean rates of hypoglycemia for IGlar were 28% lower for IDeg (A) compared with IGlar (RR = 0.72, 95% confidence interval [CI]: 0.65–0.8); 5.9 mg/dL [1/1 mmol/L, 95% CI: 0.8–5.9 mg/dL]. The estimated mean rates of hypoglycemia for IGlar were 28% lower for IDeg (A) compared with IGlar (RR = 0.72, 95% confidence interval [CI]: 0.65–0.8).
<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Duration (weeks)</th>
<th>Mean baseline values</th>
<th>Comparators</th>
<th>Basal insulin target goals</th>
<th>HbA1c, %</th>
<th>Change (±SD) from baseline to end of study</th>
<th>ETD (95% CI)</th>
<th>Change (±SD) from baseline to end of study</th>
<th>ETD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinman et al.</td>
<td>245</td>
<td>16</td>
<td>Age: 54; BMI: 29.5; Hba1c: 8.7; FPG: 184</td>
<td>IDeg 3TW vs IDegOD † vs IGlarOD</td>
<td>72–108</td>
<td>IDeg 3TW: −1.5 (1.1)</td>
<td>IGlar: −0.08 (−0.23–0.40)</td>
<td>IGlar: −0.17 (−0.15–0.48)</td>
<td>IDeg 3TW: −75.6 (63)</td>
<td>IGlar: −0.72 (−1.15–16.56)</td>
</tr>
<tr>
<td>M, R, O, P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heise et al.</td>
<td>178</td>
<td>16</td>
<td>Age: 59.1; BMI: 30.3; Hba1c: 8.5; FPG: 208</td>
<td>IDeg Asp (70/30) vs IDegAsp AF (55/45) vs IGlar</td>
<td>72–108</td>
<td>IDegAsp: −1.3 (1.1)</td>
<td>AF: −1.5 (1.4)</td>
<td>AF: −0.08 (−0.62–0.19)</td>
<td>IDegAsp: −77.4 (±63)</td>
<td>IGlar: −2.34 (−18.54–13.86)</td>
</tr>
<tr>
<td>M, R, O, C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaag et al.</td>
<td>182</td>
<td>16</td>
<td>Age: 60; BMI: 31.4; Hba1c: 8.5; FPG: 209</td>
<td>IDegAsp (70/30) vs IDegAsp AF (55/45) vs BIAsp 30</td>
<td>72–108</td>
<td>IDegAsp: −1.8 †</td>
<td>AF: −1.9 †</td>
<td>BIAsp 30: −1.8</td>
<td>Not reported</td>
<td>IDegAsp vs BIAsp 30: −17.8 (−30.2 to −5.2)</td>
</tr>
<tr>
<td>O, R, treat-to-target</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Birkeland et al.</td>
<td>457</td>
<td>26</td>
<td>Age: 56; BMI: 29; Hba1c: 8.4; FPG: not reported</td>
<td>IDegFlex vs IDegOD</td>
<td>&lt; 90</td>
<td>IDegFlex: −1.3</td>
<td>IDegOD: −0.13 (−0.29–0.03)</td>
<td>IDegFlex: −57.6</td>
<td>IDegFlex vs IDegOD: −0.9 (−8.1–6.3)</td>
<td></td>
</tr>
<tr>
<td>O, R, treat-to-target</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meneghini et al.</td>
<td>459</td>
<td>26</td>
<td>Age: 56; BMI: 30; Hba1c: 8.4; FPG: 161</td>
<td>IDegFlex vs IGlar</td>
<td>&lt; 90</td>
<td>IDegFlex: −1.28</td>
<td>IGlar: −0.04 (−0.12–0.20)</td>
<td>IDegFlex: −57</td>
<td>IDegFlex vs IGlar: −7.6 (−14.8 to −0.4)</td>
<td></td>
</tr>
<tr>
<td>Atkin et al.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bain et al.</td>
<td>118,2010</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td>O, R</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garber et al.</td>
<td>992</td>
<td>52</td>
<td>Age: 58.9; Hba1c: 8.3; FPG: 166</td>
<td>IDeg vs IGlar</td>
<td>&lt; 90</td>
<td>IDeg: −1.2</td>
<td>IGlar: −1.3</td>
<td>IGlar: −0.08 (−0.05–0.21)</td>
<td>IDeg: −43</td>
<td>IGlar: −38</td>
</tr>
<tr>
<td>Phase III</td>
<td>O, R, treat-to-target</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hollander et al.</td>
<td>172,233</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: †Trials using two formulations of insulin degludec: IDeg (A) = 600 µmol/L, 1 unit/6 mmol; IDeg (B), 900 µmol/L, 1 unit/9 mmol. ‡Abstract. †Full publication. §Statistically significant, P < 0.05. ¥Vaag = baseline for each unknown; subtracted end of study values (IDegAsp = 63, IDegAspAF = 62, BIAsp 30 = 63) from mean Hba1c of 8.5.

Abbreviations: M, multicenter; R, randomized; C, controlled; P, parallel-group; O, open-label; ETD, estimated mean treatment difference; BMI, body mass index; Hba1c, glycosylated hemoglobin; FPG, fasting plasma glucose; IDeg, insulin degludec; IGlar, insulin glargine; IDeg 3TW, insulin degludec three times a week; IDegAsp is a soluble co-formulation of IDeg (70%) and insulin aspart (IAsp, 30%); AF, alternative formulation (55% IDeg and 45% IAsp); BIAsp 30, biphasic insulin aspart 30; IDegOD, administered same time daily with evening meal; IDegFlex, administered on flexible schedule (alternating between morning and evening creating an 8–40 hour interval between basal insulin doses).
IDeg (4.4 vs 5.9 episodes/patient year, ERR = 0.75, 95% CI: 0.59–0.96; \( P = 0.021 \)). Mean total daily insulin dose was similar to baseline. Overall rates of adverse events were similar between groups.

**Comparative study with insulin detemir**

A Phase III, 26-week, open-label treat-to-target trial compared the efficacy and safety of IDeg/IAsp (IDegAsp), a coformulation of IDeg (70%) and IAsp (30%) versus basal insulin detemir (IDet).\(^{36,37}\) 548 people with type 1 diabetes (mean age = 41 years, HbA\(_1c\) = 8.3%, FPG = 189 mg/dL [10.5 mmol/L]) were randomized 2:1 to receive IDeg/Asp or detemir treatment once a day. IAsp was administered as background mealtime insulin. Similar proportions of participants completed the trial (87% for IDeg/Asp vs 86% for detemir). By the end of the trial, overall glycemic control was similar in both groups (0.73% point reduction for IDeg/Asp vs 0.68% point reduction for detemir, ETD IDegAsp–detemir = –0.05% point, 95% CI: –0.18–0.08; \( P = \text{NS} \)). FPG was reduced by 29 mg/dL (1.6 mmol/L) with IDegAsp and by 43.2 mg/dL (2.4 mmol/L) with detemir (ETD IDegAsp–detemir = 4.14 mg/dL [0.23 mmol/L], 95% CI: –0.46–0.91; \( P = 0.52 \)). Confirmed hypoglycemia was similar in both groups (39 vs 44 episodes/patient–year, ERR IDegAsp/IDet = 0.91, 95% CI: 0.76–1.09; \( P = 0.27 \)). The rate of nocturnal confirmed hypoglycemia was 37% lower with IDegAsp (3.7 vs 5.7 episodes/patient–year, ERR = 0.63, 95% CI: 0.49–0.81; \( P = 0.0003 \)). Mean total insulin daily doses were similar in both groups by the end of the study (0.86 U/kg vs 1.00 U/kg for IDegAsp and detemir groups, respectively). After 26 weeks, mean body weight had increased by 2.4 kg and 1.4 kg, respectively (ETD IDegAsp–detemir = 1.0 kg, 95% CI: 0.38–1.69; \( P = 0.0021 \)). Overall, rates for adverse events were similar between groups.

**Degludec in type 2 diabetes**

Four of these studies compared IDeg and/or different coformulations of IDeg (IDegAsp) to IGlar.\(^{18–20,32,34,38,50}\) One study compared IDeg to biphasic IAsp 30 (BIAsp 30),\(^{41,49,51}\) and one study compared flexible dosing versus once daily dosing of IDeg.\(^{19}\)

**Phase II trials**

Comparison with insulin glargine

In a 16-week, open-label, randomized, four-arm, parallel-group, treat-to-target trial, insulin-naïve participants (mean age = 54.2 years, mean HbA\(_1c\) = 8.7%, mean FPG = 184 mg/dL [10.2 mmol/L], mean BMI = 29.5 kg/m\(^2\)) received a once a day formulation of IDeg (600 nmol/mL formulation, starting dose 10 U [1 U = 6 nmol]) (IDegOD, group A, \( n = 60 \)), a three times a week formulation of IDeg (900 nmol/mL formulation, starting dose 20 U [1 U = 9 nmol]) (IDeg 3TW, group B, \( n = 62 \)), an alternative once a day IDeg formulation (900 nmol/mL formulation, starting dose 10 U [1 U = 9 nmol]) (IDeg 3TW, group B, \( n = 62 \)), or IGlar daily (starting dose 10 U [1 U = 6 nmol]) (IGlarOD, \( n = 62 \)), all in combination with metformin.\(^{34}\) All insulin was injected subcutaneously in the evening and titrated to achieve FPG 72–108 mg/dL (4.0–6.0 mmol/L).

At the end of the study period, HbA\(_1c\) was similar across treatment arms with regard to mean reduction from baseline (IDegOD [groups A and B] = –1.3%, IDeg 3TW = –1.5%, IGlarOD = –1.50; \( P = \text{NS} \)). Estimated mean HbA\(_1c\) treatment differences from IDeg in comparison with IGlar were 0.08% (95% CI: –0.23–0.40 for IDeg 3TW schedule, 0.17% (95% CI: –0.15–0.48) for group A, and 0.28% (95% CI: –0.04–0.59) for group B. Treatments were also comparable with respect to final mean reductions in FPG from baseline (IDegOD group A = –64.8 mg/dL, IDegOD group B = –75.6 mg/dL, IDeg 3TW = –75.6 mg/dL, IGlarOD = –61.2 mg/dL). At the end of the trial, mean weekly insulin dose were similar and mean body weight remained constant throughout the trial in all treatment arms. Overall rates of confirmed hypoglycemia (defined as <56 mg/dL) were low in all treatment groups, with 77%–92% of participants not reported to have had a hypoglycemic episode. Estimated odds ratios of confirmed hypoglycemic episodes by comparison with IGlar were IDeg 3TW = 0.84 (95% CI: 0.35–2.03; \( P = \text{NS} \)), IDeg group A = 0.26 (95% CI: 0.08–0.81; \( P < 0.05 \)), and IDeg group B = 0.57 (95% CI: 0.22–1.49; \( P = \text{NS} \)). The proportion of participants who had hypoglycemia in IDeg group A was lower than the proportion in the IGlar group and the IDeg three times a week group. The rate of confirmed nocturnal hypoglycemia was low and similar in all treatment groups. Body weight was stable throughout the trial in every group. A significant difference was noted between the IDeg group B and IGlar groups (1.00, 95% CI: 0.17–1.83; \( P < 0.05 \)). Overall rates of adverse effects of mild-to-moderate severity (headache, dermatitis, pruritic rash, diarrhea, stomach discomfort, and peripheral edema) were reported by 10% of participants in the IDeg three times a week group. There were few injection site reactions reported.

In another proof-of-concept trial, IDegAsp was compared to IGlar in a 16-week, multicenter, open-label, randomized, parallel-group, treat-to-target trial of insulin-naïve people...
with type 2 diabetes who were inadequately controlled on oral antidiabetic drugs. Subjects (mean age = 59.1 years, mean HbA1c = 8.5%, mean BMI = 30.3 kg/m²) were randomized to once daily IDegAsp (IDeg 70%) and IAsp (30%, n = 59), an alternative formulation (AF) of IDegAsp (AF = 55% IDeg and 45% IAsp, n = 59), or IGlar (n = 60), all in combination with metformin for 16 weeks. The insulin starting dose was 10 units administered in the abdomen (IDegAsp, AF) or thigh (IGlar). Insulin was dosed subcutaneously before dinner and titrated to a FPG target of 72–108 mg/dL (4.0–6.0 mmol/L).

After 16 weeks, mean HbA1c decreased from baseline in all treatment groups (IDegAsp = −1.31%, AF = −1.46%, IGlar = −1.29%) to comparable end of trial values (7.0%, 7.2%, and 7.1%, respectively, P = NS for all pairwise comparisons). IDegAsp was associated with a 0.11% point greater reduction in HbA1c compared with IGlar (estimated mean treatment difference = −0.11, 95% CI: −0.41–0.19), and a 0.08%-point greater reduction in HbA1c compared with AF (estimated mean treatment difference AF–IDegAsp = 0.08, 95% CI: −0.22–0.38). Mean reductions in FPG values were similar across treatment groups (IDegAsp = 122 mg/dL [6.8 mmol/L], AF = 133 mg/dL [7.4 mmol/L], IGlar = 126 mg/dL [7.0 mmol/L]). IDegAsp was associated with a 2.34 mg/dL (0.13 mmol/L) greater reduction compared with IGlar (estimated mean treatment difference [IDegAsp–IGlar] = −2.34 mg/dL, 95% CI: 18.54–13.86) and a 11.52 mg/dL (0.64 mmol/L) greater reduction in FPG compared with AF (estimated mean treatment difference [AF–IDegAsp] = 11.52 mg/dL (95% CI: −4.5–27.54)). Mean self-measured 2-hour postdinner postprandial plasma glucose (PG) increments (plasma glucose concentration 2 hours after a meal minus the plasma glucose concentration measured immediately prior to the meal) were similar for all treatments after breakfast and lunch. However, the increase in mean 2-hour postdinner plasma glucose was substantially lower for IDegAsp (2.34 mg/dL [0.13 mmol/L]) and AF (4.32 mg/dL [0.24 mmol/L]) compared with IGlar (29.34 mg/dL [1.63 mmol/L]). The estimated mean treatment difference was −24.1 mg/dL (−1.34 mmol/L) (95% CI: −44.1–to −4.1) for IDegAsp–IGlar.

No severe hypoglycemic events were reported. Rates of confirmed hypoglycemia (plasma glucose < 56 mL/minute) were lower for IDegAsp and IGlar than AF (1.2, 0.7, and 2.4 events/patient year). Nocturnal hypoglycemia occurred rarely for IDegAsp (one subject, one event) and IGlar (three subjects, three events), compared with AF (10 subjects, 27 events). At the end of the trial, mean daily insulin doses were approximately 20% lower for IDegAsp and AF than for IGlar (0.38 ± 0.16, 0.36 ± 0.16, and 0.45 ± 0.20 units/kg, respectively). Changes in mean body weight observed from baseline to week 16 for IDegAsp, AF, and IGlar were −0.4 ± 2.3 kg, 0.3 ± 2.2 kg, and −0.1 ± 3.2 kg, respectively. Adverse events with a possible or probable relation to insulin were only reported for AF. The authors concluded that IDegAsp provided comparable overall glycemic control to IGlar at similar rates of hypoglycemia, with the additional benefit of postdinner PG control.

Comparison with biphasic insulin aspart 30 (BIAsp 30)

This 16-week, open-label, treat-to-target trial investigated the efficacy and safety of IDegAsp (IDeg 70%, IAsp 30%) in insulin-naïve people with type 2 diabetes that were inadequately controlled onOADs. Subjects (mean age = 60 years, mean HbA1c = 8.5%, mean FPG = 209 mg/dL) were randomized to twice-daily IDegAsp (n = 61), BIAsp 30 (n = 62), or an alternative formulation of IDegAsp (AF, n = 59) with a higher percentage of IAsp (45%), or BIAsp 30 (n = 62), all in combination with metformin (1500 or 2000 mg/day). Insulin was dosed subcutaneously before breakfast and before the evening meal and titrated to a pre-breakfast and predinner PG target of 72–108 mg/dL.

After 16 weeks, mean HbA1c was comparable for IDegAsp, AF, and BIAsp 30 (6.7%, 6.6%, and 6.7%, respectively). Mean FPG was significantly lower for IDegAsp vs BIAsp 30 (treatment difference [TD] = −17.8 mg/dL, 95% CI: −30.2–5.2), and AF vs BIAsp 30 (TD = −15.8 mg/dL, 95% CI: −28.4–3.2). The rate of confirmed hypoglycemia was 58% lower for IDegAsp than BIAsp 30 (2.9 vs 7.3 episodes/patient year, rate ratio = 0.42 [0.23; 0.75]), while rates were similar for BIAsp 30 and AF. Nocturnal confirmed hypoglycemia was less frequent for IDegAsp (7 episodes) than AF (14 episodes) and BIAsp 30 (20 episodes). The overall rate of adverse events was similar between insulins and the majority (>99%) were mild or moderate in severity. The authors concluded that IDegAsp was safe and well tolerated and provided comparable overall glycemic control to BIAsp 30. IDegAsp was associated with a significantly lower FPG and a significantly lower rate of hypoglycemia than BIAsp 30.

Phase III trials

A study has compared the efficacy and safety of IDeg to IGlar. Both insulins were administered once daily as basal/bolus treatment in combination with mealtime IAsp ± metformin ± pioglitazone. This 1-year open-label
(different pen devices), treat-to-target trial consisted of 992 patients (mean age = 58.9 years, mean diabetes duration = 13.5 years, mean HbA1c = 8.3%, mean FPG = 166 mg/dL) who sustained HbA1c levels of 7% to 10% after a minimum of 3 months of insulin with or without oral anti-diabetic drugs. Subjects were randomized (3:1) to receive either IDeg or IGlar. Basal insulin was titrated to FPG <90 mg/dL. More than 80% of patients in both groups completed the trial. After 1 year, IDeg and IGlar achieved similar glycemic control, with HbA1c having dropped 1.2% in the IDeg group and 1.3% in the IGlar group. Estimated treatment difference IDeg–IGlar was 0.08% (95% CI: −0.05−0.21; P = NS). In both groups, 50% of subjects achieved HbA1c <7% (P = NS). FPG was reduced by 43 mg/dL with IDeg and 38 mg/dL with IGlar (ETD = −5.2 mg/dL, 95% CI: −11.7−1.1; P = NS).

Rates of nocturnal confirmed hypoglycemia (defined as <56 mg/dL or considered severe per ADA definition, occurring between midnight and 05:59 am) were 25% lower with IDeg compared with IGlar (1.4 vs 1.8 episodes/patient-year, ERR IDeg/IGlar = 0.82, 95% CI: 0.69–0.99; P = 0.0399). Similarly, rates of confirmed hypoglycemia were lower with IDeg than IGlar (11.1 vs 13.6 episodes/patient-year, ERR IDeg/IGlar = 0.82, 95% CI: 0.69–0.99; P = 0.0359). At 1 year, total mean daily insulin doses were 1.46 μg/kg and 1.42 μg/kg in the IDeg and IGlar groups respectively, with a basal/bolus split of approximately 50/50 in the two groups. Adverse events were also similar between groups. In conclusion, IDeg given as basal/bolus treatment with IAsp in people with type 2 diabetes improves long-term glycemic control with significantly lower risk for overall and nocturnal hypoglycemia than IGlar.

Flexible dosing of insulin degludec compared to insulin glargine QD

Flexible dosing of insulin degludec QD compared to insulin glargine QD with evening meal

A once-daily administration of IDeg in a flexible dosing regimen (IDeg–Flex, n = 229) was compared with IDeg once daily (OD) administered with the evening meal (n = 228). At 26 weeks, IDeg Flex and IDegOD improved HbA1c by 1.3% points and 1.1% points, respectively (ETD IDegFlex–IDegOD = −0.13% points, 95% CI: −0.29–0.03). Mean FPG was reduced by 57.6 mg/dL (IDeg Flex) and by 54 mg/dL (IDegOD) (ETD = −0.9 mg/dL, 95% CI: −8.1–6.3). Rates of confirmed hypoglycemia were 3.6 episodes/patient-year in both groups (ERR = IDeg Flex/IDegOD = 19.8, 95% CI: 14.2–27.4). The ratio of nocturnal confirmed hypoglycemia was 0.6 episodes/patient-years in both groups (ERR = 21.2, 95% CI: 11.9–38.2). The study concluded that IDeg insulin can be dosed flexibly at any time of day without affecting glycemic control or risk of hypoglycemia.

Safety and tolerability

Overall rates of adverse events were similar between groups with no treatment-specific pattern or clustering.

Hypoglycemia

In all of these trials, confirmed hypoglycemia was defined as a value <56 mg/dL (3.1 mmol) or classified as “severe” if requiring assistance from another person. Confirmed nocturnal hypoglycemic episodes were defined as time of onset between 2300 and 0559 hours (inclusive)
and not defined. Hypoglycemic events in clinical studies of type 1 and type 2 diabetes are summarized in Tables 3 and 4, respectively.

In type 1 diabetes, IDeg significantly reduced the incidence of nocturnal hypoglycemic events by 25% to 58% compared to IGlar and detemir. This effect was seen consistently in all the trials. Except in one trial, the overall incidence of hypoglycemia was comparable to that of IGlar and insulin detemir. In a small (n = 28) double-blind, two-period, crossover trial, the counter-regulatory hormone responses of both IDeg and IGlar were compared in type 1 patients after eliciting a period of hypoglycemia. The induction of hypoglycemia with IDeg resulted in a significantly greater counterregulatory hormone response compared to IGlar, indicating that enhanced counterregulation may contribute to the observed reduced hypoglycemia risk for IDeg compared with IGlar in patients with type 1 diabetes.

In the clinical studies that evaluated hypoglycemia in patients with type 2 diabetes, IDeg administered once a day was compared to IGlar, flexible dosing of IDeg, and BIAsp 30. When compared to IGlar, there was no statistically significant difference in the overall incidence of hypoglycemia or nocturnal hypoglycemia by IDeg. However, it is interesting to note that there was a higher mean rate of hypoglycemic episodes reported in the three-dose-per-week IDeg group than in the once-daily groups. This may be because of the use of larger doses of insulin that had to be given at every injection to cover the weekly insulin requirements (ie, the starting dose for the three-dose-per-week group was double that of the once-daily group dose).

One study with a duration of 52 weeks demonstrated that the rate of overall confirmed hypoglycemia was 18% lower with IDeg than with IGlar. This study also noted that IDeg resulted in a 25% lower rate of nocturnal hypoglycemia than IGlar. In all other studies, the incidence of nocturnal hypoglycemia in patients with type 2 diabetes treated with IDeg was similar to those treated with IGlar or not reported.

### Body weight

The effect of IDeg on body weight is unclear because change in body weight at end of study was not reported in all trials with type 1 and type 2 diabetes. Based on the limited information available, it appears that mean body weight remains stable with only small changes observed after treatment with IDeg compared to IGlar. On the other hand, a 26-week study found that there was less weight gain in the detemir group compared with the IDegAsp group (ETD = 1.0 kg, 95% CI: 0.38–1.69; P = 0.0021).

### Insulin doses

At the end of study duration, mean total daily insulin doses were similar between IDeg and IGlar groups, divided 50:50 between the basal and bolus components for both groups. Only one study reported on changes in basal insulin requirements from pre- to post-trial. Small increases in mean daily basal insulin dose was also observed from pretrial to end of trial for IDeg (A) (from 29 ± 12 units to 30 ± 13 units) and IGlar (from 23 ± 11 units to 26 ± 13 units). Another 16-week study found that mean daily insulin doses at the end of trial were 20% lower for IDeg than IGlar (0.38 ± 0.16 vs 0.45 ± 0.2, respectively). Two studies did not report on insulin doses used.

### Mitogenic potential

Native insulin binds with low affinity to the insulin-like growth factor (IGF-I) receptor, a receptor molecule that shares constant similarities with the insulin receptor but

---

**Table 3: Incidence of hypoglycemia in type 1 diabetes**

<table>
<thead>
<tr>
<th>Study</th>
<th>Weeks</th>
<th>Confirmed hypoglycemia &lt; 56 mg/dL (3.0 mmol/L)</th>
<th>Nightly hypoglycemia</th>
<th>Nocturnal hypoglycemia vs IGlar (ERR [95% CI])</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birkeland et al</td>
<td>16</td>
<td>47.9, 59.5, 66.2</td>
<td>No Change (1.07 (0.89–1.28))</td>
<td>25% (0.75 (0.59–0.96))</td>
</tr>
<tr>
<td>Russell-Jones et al, Heller et al</td>
<td>52</td>
<td>42.5 vs 40.2</td>
<td>No Change (1.07 (0.89–1.28))</td>
<td>25% (0.75 (0.59–0.96))</td>
</tr>
<tr>
<td>Hirsch et al</td>
<td>26</td>
<td>39 vs 44</td>
<td>No insulin detemir</td>
<td>37% (0.63 (0.49–0.81))</td>
</tr>
</tbody>
</table>

**Notes:** 1Statistically significant (P < 0.05); 2Trials using two formulations of insulin degludec (IDeg (A), 600 μmol/L, 1 unit/6 mmol; IDeg (B), 900 μmol/L, 1 unit/9 mmol); 3IDeg (70%); 4Asp 30%; 5ERR, estimated rate ratio; 6IGlar, insulin glargine; 7Nightly hypoglycemic episodes was defined as confirmed hypoglycemia < 56 mg/dL occurring between 2300 and 0559 hours (inclusive) and not defined in the following studies.
that has more marked mitogenic and antiapoptotic effects.\(^5\)

The use of structurally modified insulin analogue molecules may lead to different chemical interactions with the binding sites of the receptor molecule (the insulin receptor isofoms [A and B] and the IGF-1 receptor [IGF-IR]).

In vitro studies indicate that the long-acting analogs IGlár and detemir stimulate mitogenic pathways more actively than native insulin via both the IR isoforms and IGF-IR. Insulin analogues display IGF-I-like mitogenic and antiapoptotic activities in cultured cancer cells.\(^44\) Detemir has a relatively low affinity for the insulin receptor compared to human insulin, and has been shown to preserve the relative affinity ratio for insulin receptors:IGF-1 receptors and the insulin receptor dissociation rate seen for natural human insulin. As a result, there are fewer concerns about increased mitogenicity with insulin detemir.\(^55,56\)

However, in vitro studies of IGlár demonstrate that glargine binds preferentially to insulin-like growth factor-1 (IGF-1) receptors rather than to insulin receptors. This may create a mitogenic potential, especially with long-term use.\(^55,57\) In animal studies, glargine did not promote tumor growth despite administration at supraphysiological concentrations (nanomolar/micromolar) that are unlikely to be observed in clinical practice as the doses needed to produce these concentrations are liable to lead to hypoglycemia.\(^59\)

Furthermore, glargine in vivo is rapidly transformed into its metabolites, the metabolic and mitogenic characteristics of which have been shown to be broadly equal to those of human insulin. Thus, the suggestion of increased relative mitogenic potency of IGlár seen in some cell lines does not appear to carry over to the in vivo situation in animals and humans.\(^58,59\)

In contrast, epidemiological studies published in 2009 suggested an increased risk of cancer associated with IGlár.\(^60\) At the current time, the US Food and Drug Administration (FDA) has determined that the evidence presented in these studies is inconclusive due to methodological limitations. The FDA is working with the manufacturer of Lantus and the US Department of Veterans Affairs to further evaluate the long-term risk of cancer and IGlár.\(^64\)

Therefore, newly developed insulin should not display increased affinity to the insulin-like growth factor receptor, increased “on” time to the insulin receptor, or other potential mitogenic signals in preclinical and clinical testing.\(^65\) The in vitro mitogenicity has been investigated and IDeg was found to have a low IGF-1 receptor binding affinity and a low mitogenic/metabolic potency ratio.\(^56,57\) The clinical relevance of this finding has yet to be confirmed.

### Conclusion

IDeg demonstrates potential use as an ultralong-acting basal insulin analogue with a smooth time-action profile of more than 42 hours.\(^1\) This unique characteristic allows a more flexible once daily dosing regimen within 8 to 40 hours of administration, thus allowing injection times to be changed from day to day without compromising glycemic control or insulin sensitivity.
safety. In a proof-of-concept trial, IDeg was evaluated for potential use in a thrice-weekly dosing schedule in insulin-naïve subjects with type 2 diabetes. This trial demonstrated that IDeg administered three times a week provides equivalent glycemic control but with a higher rate of hypoglycemic episodes compared to the once daily IDeg and IGLar groups. The clinical significance of this dosing regimen remains unknown, as a dosing schedule of every 2 to 3 days may affect adherence and short-term dose adjustments for activity.

In published clinical trials, IDeg has been studied in more than 3000 subjects with type 1 or type 2 diabetes (Tables 1 and 2). There were no reported differences at the end of study between IDeg and its comparators in the reduction of the primary efficacy end-point of hemoglobin A1c in subjects with type 1 and type 2 diabetes. Reductions in mean FPG concentrations were also much the same across all the treatment groups in patients with type 1 diabetes. However, in studies of type 2 diabetes, mean FPG was significantly reduced with flexible dosing of IDeg compared to IGLar and BIAsp 30.

IDeg unequivocally demonstrated a significant reduction in nocturnal hypoglycemia compared to IGLar and detemir only in type 1 diabetes (Table 3). Overall, the incidence of hypoglycemic episodes was not remarkably different between IDeg and its comparators in both type 1 and 2 clinical trials. However, in type 2 diabetes, IDeg reduced the incidence of hypoglycemia by 18% and 58% compared to IGLar and BIAsp 30, respectively. Only one trial reported results on health-related quality of life, but this only showed improved mental well-being with IDeg compared to IGLar.

Limitations of the available studies include their open-label design, relatively short duration, and often inadequate sample sizes. Most of the studies were not available in full but were presented as abstracts in conference proceedings. More information will become available in the near future with the completion or near completion of some Phase III clinical trials. It was not possible to draw conclusions on quality of life, economic considerations, dosage and administration, or mortality. The place of IDeg in routine clinical practice remains to be determined.

Disclosure
The authors report no conflicts of interest in this work.

References

20. Akin SI, Bain SC, Gough S, et al. Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes. Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting; Sep 2011; Lisbon, Portugal.


